The latest financial statement is for the quarter ending 2025-06-30.
| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 5,183 |
| Non-cash operating lease expense | 730 |
| Accrued expenses and other current liabilities | 311 |
| Amortization of premium/discount on marketable securities | -401 |
| Realized gain on investments | 1 |
| Net loss | -49,076 |
| Prepaid expenses and other current assets | 519 |
| Other non-current assets | -72 |
| Operating lease liabilities | -508 |
| Accounts payable | -416 |
| Depreciation and amortization | 253 |
| Net cash provided (used) in operating activities | -44,372 |
| Proceeds from sales and maturities of marketable securities | 39,298 |
| Purchases of property and equipment | 354 |
| Purchases of marketable securities | 5,917 |
| Net cash provided (used) by investing activities | 33,027 |
| Proceeds from stock options exercised | 273 |
| Proceeds from issuance of common stock, net of offering costs | 13,267 |
| Net cash provided by financing activities | 13,540 |
| Net change in cash and cash equivalents | 2,195 |
Vigil Neuroscience, Inc. (VIGL)
Vigil Neuroscience, Inc. (VIGL)